ArteraAI
Develops AI prognostic tests to personalize cancer treatment plans and improve outcomes.
What they do
ArteraAI develops digital prognostic and predictive tests utilizing artificial intelligence to analyze pathology images. Healthcare providers use these tests to personalize prostate cancer treatment, determining which patients will benefit from hormone therapy or if they can safely avoid intensive treatments.
The record
- Vertical
- Oncology
- Sub-segment
- Precision medicine platform
- Product type
- Software as a medical device
- Stage
- Series B
- Headquarters
- San Francisco, United States
- Region
- North America
- Founded
- 2020
- Total funding
- $110M raised
Notable investors: Coatue, Breyer Capital, Section 32, Marc Benioff.